Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...

Mean absorption is shown ... and remained relatively constant in Norgen's cf-DNA/cf-RNA Preservative Tubes. Image Credit: Norgen Biotek Corporation Figure 4. Prevent cell lysis and the release ...

The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...

Yale scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related ...

The last week’s events in Queensland won’t have assuaged any fears over planning for the biggest show on earth.

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...